Document is current
Any future updates will be listed below
-
Authors
Haghighat Jahromi, Amin https://orcid.org/0000-0002-8263-903X
Barkauskas, Donald A.
Zabel, Matthew
Goodman, Aaron M.
Frampton, Garret
Nikanjam, Mina
Hoh, Carl K.
Kurzrock, Razelle
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32-4T32EB005970)
- License Information
-
More Information
Article History
Received: 7 September 2020
Accepted: 21 November 2020
First Online: 9 December 2020
Ethics approval and consent to participate
: This study was performed and consent obtained in accordance with the guidelines of the UCSD Internal Review Board (PREDICT [Profile Related Evidence Determining Individualized Cancer Therapy], protocol; NCT02478931).
: The manuscript has been seen and approved by all authors. We certify that the manuscript is not under consideration for publication and has not been published elsewhere in any public medium including electronic journals and computer databases.
: Razelle Kurzrock receives research funding from Genentech, Incyte, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Grifols, Konica Minolta, Omniseq, and Guardant, as well as consultant fees from Loxo, X Biotech, NeoMed, and Actuate Therapeutics, speaker fees from Roche, and an equity interest in IDbyDNA and Curematch Inc. Aaron Goodman receives speaking fees from Seattle Genetics and consulting fees from Jazz Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin, and Navican. Donald Barkauskas has a close relation who is employed by Genentech.
